ADC Therapeutics SA Research and Development Expense
ADC Therapeutics SA (ADCT) reported Research and Development Expense of $17.37 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-13
- ADC Therapeutics SA research and development expense for the quarter ending 2026-06-30 was $17.37M, a 42.29% decline year-over-year.
- ADC Therapeutics SA research and development expense for the quarter ending 2026-03-31 was $19.88M, a 31.29% decline year-over-year.
- ADC Therapeutics SA research and development expense for the quarter ending 2025-12-31 was $18.18M, a 32.90% decline year-over-year.
- ADC Therapeutics SA research and development expense for the quarter ending 2025-09-30 was $26.80M, a 17.53% decline year-over-year.
- ADC Therapeutics SA research and development expense for fiscal 2025 was $104.00M, a 5.13% decline from fiscal 2024.
- ADC Therapeutics SA research and development expense for fiscal 2024 was $109.63M, a 13.76% decline from fiscal 2023.
- ADC Therapeutics SA research and development expense for fiscal 2023 was $127.13M, a 31.82% decline from fiscal 2022.
- ADC Therapeutics SA research and development expense for fiscal 2022 was $186.46M.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $17.37M 10-Q · filed 2026-08-13 | $37.24M 10-Q · filed 2026-08-13 | $55.43M derived: sum of 3 quarters · filed 2026-08-13 | $82.23M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $19.88M 10-Q · filed 2026-05-04 | $38.06M derived: sum of 2 quarters · filed 2026-05-04 | $64.86M derived: sum of 3 quarters · filed 2026-05-04 | $94.95M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $18.18M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | $44.99M derived: sum of 2 quarters · filed 2026-03-10 | $75.08M derived: sum of 3 quarters · filed 2026-08-13 | $104.00M 10-K · filed 2026-03-10 |
| 2025-09-30 | $26.80M 10-Q · filed 2025-11-10 | $56.89M derived: sum of 2 quarters · filed 2026-08-13 | $85.82M 10-Q · filed 2025-11-10 | $112.92M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $30.09M 10-Q · filed 2026-08-13 | $59.02M 10-Q · filed 2026-08-13 | $86.12M derived: sum of 3 quarters · filed 2026-08-13 | $118.62M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $28.93M 10-Q · filed 2026-05-04 | $56.03M derived: sum of 2 quarters · filed 2026-05-04 | $88.53M derived: sum of 3 quarters · filed 2026-05-04 | $112.83M derived: sum of 4 quarters · filed 2026-05-04 |
| 2024-12-31 | $27.10M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | $59.60M derived: sum of 2 quarters · filed 2026-03-10 | $83.90M derived: sum of 3 quarters · filed 2026-03-10 | $109.63M 10-K · filed 2026-03-10 |
| 2024-09-30 | $32.50M 10-Q · filed 2025-11-10 | $56.80M derived: sum of 2 quarters · filed 2025-11-10 | $82.53M 10-Q · filed 2025-11-10 | $112.86M derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | $24.30M 10-Q · filed 2025-08-12 | $50.03M 10-Q · filed 2025-08-12 | $80.36M derived: sum of 3 quarters · filed 2025-08-12 | $107.44M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $25.73M 10-Q · filed 2025-05-14 | $56.06M derived: sum of 2 quarters · filed 2025-05-14 | $83.14M derived: sum of 3 quarters · filed 2025-05-14 | $114.49M derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | $30.33M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $57.41M derived: sum of 2 quarters · filed 2025-03-27 | $88.75M derived: sum of 3 quarters · filed 2025-03-27 | $127.13M 10-K · filed 2025-03-27 |
| 2023-09-30 | $27.08M 10-Q · filed 2024-11-07 | $58.42M derived: sum of 2 quarters · filed 2024-11-07 | $96.80M 10-Q · filed 2024-11-07 | |
| 2023-06-30 | $31.34M 10-Q · filed 2024-08-06 | $69.72M 10-Q · filed 2024-08-06 | ||
| 2023-03-31 | $38.38M 10-Q · filed 2024-05-06 | |||
| 2022-12-31 | $186.46M 10-K · filed 2024-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LIFECORE BIOMEDICAL, INC. DE (LFCR) | United States | $0.163B | -8.50 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |